Drug Makers In Japan Want Price Cap Revisions
This article was originally published in PharmAsia News
Japanese pharmaceutical makers are asking the government to reconsider its decision to lower the cap on drug prices by 5.2 percent. The new price limits, which are lower than the 6.7 percent decrease of two years ago, are set to take effect in April. Drug makers contend the lowered caps do not give adequate consideration to the cost of developing new drugs. Chugai Pharmaceutical estimates it will suffer a 7.2 percent reduction in the prices it can charge for its products. (Click here for more - a subscription may be required
You may also be interested in...
US FDA investigators are more likely to cite cell and gene therapy manufacturers for facilities and production deficiencies, agency says, while industry reports difficulties complying with drug GMP requirements that are not always applicable to cell and gene therapies.
GSK’s antibody-drug conjugate may reach the market first, but CAR-T therapies from Bristol/bluebird and Janssen/Legend are close behind, and all three big pharmas have programs in earlier-stage disease.
Manufacturers warned to keep better electronic records and not falsify data in recent warning letters, ICH adds three residual solvent limits for pharmaceuticals, and the Polish authority hits firm for GMP noncompliance.